Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
View Patent ↗The present invention provides compositions and methods for reversibly inhibiting S-adenosyl-L-homocysteine (SAH) hydrolase. The compounds of the present invention can be used in combination with an anti-hemorrhagic viral infection agent, an immunosuppressant, a homocysteine lowering agent, or an anti-neoplasm agent. The compositions and methods of the present invention can be used for the prevention and treatment of hemorrhagic virus infection, autoimmune diseases, autograft rejection, neoplasm, hyperhomocysteineuria, cardiovascular disease, stroke, Alzheimer's disease, or diabetes.
1. A method for suppressing a T-cell mediated autoimmune response in a patient in need of treatment for multiple sclerosis, which method comprises administering to said patient an effective amount of methyl 4-(Adenin-9-yl)-2-hydroxybutanoate or a pharmaceutically acceptable salt thereof, thereby suppressing T-cell mediated autoimmune response autoimmunity in said patient.
2. The method of claim 1 , wherein the administration is oral, parenteral, intranasal, topical, or injectable.
3. The method of claim 1 , wherein methyl 4-(Adenin-9-yl)-2-hydroxybutanoate or a pharmaceutically acceptable salt thereof is formulated in a solid or liquid dosage form.
4. The method of claim 1 , wherein methyl 4-(Adenin-9-yl)-2-hydroxybutanoate or a pharmaceutically acceptable salt thereof is formulated for oral administration in a dosage ranging from about 0.1 to about 20 mg/kg per day.
5. The method of claim 1 , wherein methyl 4-(Adenin-9-yl)-2-hydroxybutanoate or a pharmaceutically acceptable salt thereof is formulated for injectable administration in a dosage ranging from about 0.1 to about 20 mg/kg per day.
6. The method of claim 5 , wherein said injectable administration is selected from the group consisting of intracavernous injection, subcutaneous injection, intravenous injection, intramuscular injection, and intradermal injection.
7. A method for suppressing T-cell proliferation in a patient in need of treatment for multiple sclerosis, which method comprises administering to said patient an effective amount of methyl 4-(Adenin-9-yl)-2-hydroxybutanoate or a pharmaceutically acceptable salt thereof, thereby suppressing T-cell proliferation in said patient, wherein the administration is parenteral, oral, intranasal or injectable.
8. The method of claim 7 , wherein methyl 4-(Adenin-9-yl)-2-hydroxybutanoate or a pharmaceutically acceptable salt thereof is formulated in a solid or liquid dosage form.
9. The method of claim 7 , wherein methyl 4-(Adenin-9-yl)-2-hydroxybutanoate or a pharmaceutically acceptable salt thereof is formulated for oral administration in a dosage ranging from about 0.1 to about 20 mg/kg per day.
10. The method of claim 7 , wherein methyl 4-(Adenin-9-yl)-2-hydroxybutanoate or a pharmaceutically acceptable salt thereof is formulated for injectable administration in a dosage ranging from about 0.1 to about 20 mg/kg per day.
11. The method of claim 10 , wherein said injectable administration is selected from the group consisting of intracavernous injection, subcutaneous injection, intravenous injection, intramuscular injection, and intradermal injection.